Alaska Permanent Fund’s Royalty Pharma RPRX Stock Holding History

Alaska Permanent Fund’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-94,551	Closed	-$3.1M	–	362
2025 Q1	$3.1M	Hold	94,551	–	–	0.04%	173
2024 Q4	$2.41M	Hold	94,551	–	–	0.04%	259
2024 Q3	$2.67M	Hold	94,551	–	–	0.04%	245
2024 Q2	$2.66M	Buy	94,551 +10,761	+13%	+$298K	0.04%	249
2024 Q1	$2.54M	Sell	83,790 -1,781	-2%	-$52.5K	0.04%	252
2023 Q4	$2.4M	Sell	85,571 -161,541	-65%	-$4.44M	0.04%	259
2023 Q3	$6.71M	Sell	247,112 -165,604	-40%	-$4.92M	0.13%	89
2023 Q2	$12.7M	Buy	+412,716	New	+$14M	0.25%	48
2022 Q4	$7.24M	Buy	183,054 +8,789	+5%	+$367K	0.12%	63
2022 Q3	$7M	Buy	174,265 +27,611	+19%	+$1.18M	0.13%	52
2022 Q2	$6.17M	Buy	146,654 +146,632	+666,509%	+$6.01M	0.09%	60
2022 Q1	$1K	Buy	+22	New	+$864	﹤0.01%	352

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Alaska Permanent Fund's RPRX Position: Q2 2025 in Review

Alaska Permanent Fund sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 94,551 shares — an estimated $3.1M sold.

Alaska Permanent Fund first reported a position in RPRX in Q1 2022 and held it in 12 quarters. The position peaked at $12.7M in Q2 2023. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Alaska Permanent Fund reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Alaska Permanent Fund sold 94,551 Royalty Pharma shares in Q2 2025, an estimated $3.1M.
Alaska Permanent Fund first reported a position in Royalty Pharma in Q1 2022 and held it in 12 quarters.
Alaska Permanent Fund's Royalty Pharma position peaked at $12.7M in Q2 2023.
454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Alaska Permanent Fund's 13F filing for Q2 2025, filed 14 Aug 2025.